Anteros launch by BMS/BioMotiv uses Yale technology

Bristol-Myers Squibb and BioMotiv have launched Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

The intellectual property behind Anteros was first developed by Yale University and in-licensed by Bristol-Myers Squibb and subsequently assigned to Anteros. more